Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Trial Profile

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Molindone (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms CHIME 2
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 18 Sep 2017 According to a Supernus Pharmaceuticals media release, Current enrollment is at approximately 56% and the company continue to expect enrollment through mid-2018.
    • 18 Sep 2017 According to a Supernus Pharmaceuticals media release, Based on the predefined criteria for dropping a dose arm, the lower dose of 18 mg will be eliminated. All patients will be randomized to either the 36 mg dose arm or placebo until the predetermined total number of patients are enrolled without changing the size of the trials. Implementation of these changes will start immediately.
    • 18 Sep 2017 According to a Supernus Pharmaceuticals media release, a planned interim analysis carried out by an independent third party has been completed and both trials (CHIME 1 & CHIME 2) will continue through to completion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top